Virios therapeutics ceo highlights novel therapeutic approach for treating fibromyalgia and irritable bowel syndrome in stock news now video interview

Atlanta--(business wire)---- $viri #biotech--virios therapeutics, inc. (nasdaq: viri), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, announced today that chairman and ceo, greg duncan, highlighted the company's novel combination antiviral development approach, its ongoing phase 2b trial fibromyalgia trial and plans for expanded pipeline programs in irritable bowel syndrome (ibs) and fatigue related disorders during a video interview w
VIRI Ratings Summary
VIRI Quant Ranking